Skip to main content
TipRanks
Go Ultimate75% OFF

DR.WU Skincare Co., Ltd. (6523) AI Stock Analysis

TW:6523

DR.WU Skincare Co., Ltd.

(TPEx:6523)

Select Model
Rating:73Outperform
Price Target:TWD 87.00▲(7.01% Upside)
Action:initiatedcoverage
Date:11/10/26

Strong balance sheet, cash flows, and attractive low P/E with high dividend yield are the primary positives supporting the score; weak technical momentum from price below moving averages and negative MACD is the main offset.

Positive Factors
Conservative Balance SheetMinimal leverage gives DR.WU substantial financial flexibility and resilience through changing demand conditions. Strong returns on equity also indicate efficient use of capital, supporting continued operations and investment without the funding pressure associated with a heavily indebted balance sheet.
Negative Factors
Revenue and Earnings ContractionRecent contraction in sales and net income signals weakening demand momentum and reduces near-term operating leverage. If the slowdown persists, it could constrain reinvestment, dilute the benefits of the company's strong margins, and make future earnings growth more dependent on renewed consumer demand.

DR.WU Skincare Co., Ltd. (6523) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%TW:6523-24.45%SPY+14.28%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 3.87B
Dividend Yield
12.30%
Average Volume (3M)
27.05K
Price to Earnings (P/E)
12.6
Beta (1Y)
0.16
Revenue Growth
-11.85%
EPS Growth
-23.46%
Country
TW
Employees
150
Sector
General
Sector Strength
55
Industry
Household & Personal Products

DR.WU Skincare Co., Ltd. Business Overview & Revenue Model

Company Description

Dr. Wu Skincare Co., Ltd. is a company that develops and distributes a broad spectrum of skincare and cosmetic products, serving both the Taiwanese domestic market and an international clientele. Their comprehensive product range includes facial clea...

DR.WU Skincare Co., Ltd. Financial Statement Overview

Summary

High margins, negligible debt, and strong cash conversion indicate robust fundamentals, though recent revenue and profit declines introduce some near-term uncertainty.

Income Statement

62Positive

Balance Sheet

93Very Positive

Cash Flow

88Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.07B1.17B1.24B1.14B926.79M1.11B
Gross Profit717.19M805.59M878.08M814.02M658.01M694.36M
EBITDA362.22M452.53M604.58M535.46M434.30M385.02M
Net Income297.83M350.27M476.25M424.73M339.98M296.24M
Balance Sheet
Total Assets1.64B1.59B1.75B1.77B1.78B1.83B
Cash, Cash Equivalents and Short-Term Investments1.00B836.02M908.72M1.28B1.37B1.41B
Total Debt35.55M40.98M46.77M5.05M15.68M25.50M
Total Liabilities370.50M235.86M294.71M291.12M254.22M296.10M
Stockholders Equity1.27B1.35B1.46B1.47B1.53B1.53B
Cash Flow
Free Cash Flow369.44M335.01M434.43M389.16M324.24M286.23M
Operating Cash Flow375.22M340.92M437.18M392.44M325.83M289.60M
Investing Cash Flow103.39M128.40M-89.21M-108.64M-332.73M812.05M
Financing Cash Flow-461.05M-460.49M-505.36M-460.47M-370.21M-785.36M

DR.WU Skincare Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:6523 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:6703TW:670377OutperformTWD 3.44B8.36―7.77%5.97%37.00%
TW:6523TW:652373OutperformTWD 3.63B12.63―12.30%-11.85%-23.46%
TW:1730TW:173071OutperformTWD 3.19B10.48―5.95%1.66%8.74%
TW:4439TW:443959NeutralTWD 3.72B10.54―4.14%19.84%223.34%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:5321TW:532142NeutralTWD 3.36B-17.46――-21.62%-494.73%
TW:4120TW:412040UnderperformTWD 3.85B-6.75―8.91%3.77%-78.32%

* General Sector Average

Performance Comparison

0%50%100%TW:6523TW:1730TW:4120TW:4439TW:5321TW:6703Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:6523 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:6523DR.WU Skincare Co., Ltd.81.30-25.40-23.81%
TW:1730Farcent Enterprise Co., Ltd.50.400.290.58%
TW:4120Orient Europharma Co., Ltd.44.902.736.48%
TW:4439TST Group Holding Ltd.98.0010.9112.53%
TW:5321United Recommend International Co., Ltd.57.2018.5047.80%
TW:6703Shiny Brands Group Co., Ltd.94.50-1.08-1.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026